Mannatech Operating Expenses 2010-2024 | MTEX

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Revenue Gross Profit Operating Income EBITDA Net Income Shares Outstanding

Mannatech operating expenses from 2010 to 2024. Operating expenses can be defined as the sum of all operating expenses for the given industry.

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Revenue Gross Profit Operating Income EBITDA Net Income Shares Outstanding

Mannatech operating expenses from 2010 to 2024. Operating expenses can be defined as the sum of all operating expenses for the given industry.

Related Stocks
Company Name	Market Cap
Zoetis (ZTS)	$76.8B
Chugai Pharmaceutical (CHGCY)	$66.9B
Takeda Pharmaceutical (TAK)	$42.4B
Sandoz Group AG (SDZNY)	$20.6B
Merck (MKKGY)	$20B
Astellas Pharma (ALPMY)	$17.7B
United Therapeutics (UTHR)	$16.6B
Summit Therapeutics (SMMT)	$16B
Neurocrine Biosciences (NBIX)	$15.3B
Shionogi (SGIOY)	$12.5B
Orion OYJ (ORINY)	$7.5B
Madrigal Pharmaceuticals (MDGL)	$7.1B
Stevanato Group S.p.A (STVN)	$6.5B
Corcept Therapeutics (CORT)	$6.4B
Hikma Pharmaceuticals Plc (HKMPF)	$5.9B
Ionis Pharmaceuticals (IONS)	$5.2B
Ono Pharmaceutical (OPHLF)	$4.9B
Grifols, S.A (GRFS)	$4.8B
Crinetics Pharmaceuticals (CRNX)	$3.7B
Catalyst Pharmaceuticals (CPRX)	$2.9B
Recursion Pharmaceuticals (RXRX)	$2.8B
AMNEAL PHARMACEUTICALS, INC (AMRX)	$2.7B
Centessa Pharmaceuticals (CNTA)	$2.2B
Soleno Therapeutics (SLNO)	$2.1B
Hypermarcas (HYPMY)	$1.9B
NewAmsterdam Pharma (NAMS)	$1.9B
Indivior (INDV)	$1.7B
BioCryst Pharmaceuticals (BCRX)	$1.7B
Evotec AG (EVO)	$1.5B
Guardian Pharmacy Services (GRDN)	$1.4B